A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: Detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus

Transfusion

Volumn 48, Issue 6, 2008, Pages 1198-1206

  Li, Lei ^b   Chen, Pei Jer ^b   Chen, Ming Hung ^b   Chak, Kin Fu ^b   Lin, Kuo Sin ^b   Tsai, Su Jen Lin ^a  

^a Taiwan Blood Services Foundation   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; COST EFFECTIVENESS ANALYSIS; ENZYME IMMUNOASSAY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEIC ACID AMPLIFICATION; PILOT STUDY; POLYMERASE CHAIN REACTION; SCREENING TEST; SEROLOGY; TAIWAN; VIRUS DETECTION; VIRUS LOAD;

EID: 84984571751     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01672.x     Document Type: Article

References (30)

1. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004 86 : 83 91.
2. Coste J, Reesink HW, Engelfriet CP, Laperche S, Brown S, Busch MP, Cuijpers HT, Elgin R, Ekermo B, Epstein JS, Flesland O, Heier HE, Henn G, Hernandez JM, Hewlett IK, Hyland C, Keller AJ, Krusius T, Levicnik-Stezina S, Levy G, Lin CK, Margaritis AR, Muylle L, Niederhauser C, Pastila S, Pillonel J, Pineau J, van der Poel CL, Politis C, Roth WK, Sauleda S, Seed CR, Sondag-Thull D, Stramer SL, Strong M, Vamvakas EC, Velati C, Vesga MA, Zanetti A. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang 2005 88 : 289 303.
3. Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000 40 : 1165 8.
4. Velati C, Fomiatti L, Baruffi L, Romanò L, Zanetti A. Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003). Euro Surveill 2005 10 : 12 4.
5. Seed CR, Cheng A, Ismay SL, Bolton WV, Kiely P, Cobain TJ, Keller AJ. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002 42 : 1365 72.
6. Murokawa H, Yoshikawa A, Ohnuma H, Iwata A, Katoh N, Miyamoto M, Mine H, Emura H, Todokoro K. Epidemiology of blood donors in Japan, positive for hepatitis B virus and hepatitis C virus by nucleic acid amplification testing. Vox Sang 2005 88 : 10 6.
7. Laperche S. Blood safety and nucleic acid testing in Europe. Euro Surveill 2005 10 : 3 4.
8. Stramer SL. US NAT yield: where are we after 2 years? Transfus Med 2002 12 : 243 53.
9. Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006 36 : S33 44.
10. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000 15 : E3 6.
11. Margaritis AR, Brown SM, Seed CR, Kiely P, D'Agostino B, Keller AJ. Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA. Transfusion 2007 47 : 1783 93.
12. Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol 2006 44 : 39 46.
13. Roche Molecular Systems. COBAS AmpliScreen HBV test package insert, Version 3. Branchburg (NJ) : Roche Molecular Systems 2006.
14. Allain JP. Epidemiology of hepatitis B virus and genotype. J Clin Virol 2006 36 : S12 7.
15. US Food and Drug Administration. Guidance for industry: in the manufacture and clinical evaluation of in vitro tests to detect nucleic acid sequences of human immunodeficiency viruses types 1 and 2. 1999 Dec.
16. US Food and Drug Administration. Draft guidance for industry: use of nucleic acid tests on pooled and individual samples from donors of whole blood and blood components for transfusion to adequately and appropriately reduce the risk of transmission of HIV-1 and HCV. 2002 Mar.
17. Koppelman MH, Sjerps MC, Reesink HW, Cuypers HT. Evaluation of COBAS AmpliPrep nucleic acid extraction in conjunction with COBAS AmpliScreen HBV DNA, HCV RNA and HIV-1 RNA amplification and detection. Vox Sang 2005 89 : 193 200.
18. Koppelman MH, Assal A, Chudy M, Torres P, de Villaescusa RG, Reesink HW, Lelie PN, Cuypers HT. Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations. Transfusion 2005 45 : 1258 66.
19. Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M Polish Blood Transfusion Service Viral Study Group. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology 2006 44 : 1666 74.
20. Lelie N, Heaton A. Hepatitis B - a review of the role of NAT in enhancing blood safety. J Clin Virol 2006 36 : S1 2.
21. Kleinman SH, Strong DM, Tegtmeier GG, Holland PV, Gorlin JB, Cousins C, Chiacchierini RP, Pietrelli LA. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion 2005 45 : 1247 57.
22. Wang JT, Wang TH, Sheu JC, Shih LN, Lin JT, Chen DS. Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis 1991 163 : 397 9.
23. Shih LN, Sheu JC, Wang JT, Huang GT, Yang PM, Lee HS, Sung JL, Wang TH, Chen DS. Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction. J Med Virol 1990 32 : 257 60.
24. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002 40 : 4068 71.
25. Inaba S, Ito A, Miyata Y, Ishii H, Kajimoto S, Tanaka M, Maruta A, Saito S, Yugi H, Hino M, Tadokoro K. Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion. Transfusion 2006 46 : 2028 9.
26. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007 47 : 1197 205.
27. Rodgers C, Lin KT, Wu YW, Lee YJ, Chen JW, Lin KC. Evaluation of a new HCV combination assay in the Taiwanese blood donor population. Vox Sang 2006 91 : s62.
28. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007 106 : 148 55.
29. Tsai MC, Kee KM, Chen YD, Lin LC, Tsai LS, Chen HH, Lu S-N. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol 2007 22 : 92 8.
30. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 2004 44 : 1332 9.